Review



glun2b n terminus  (Alomone Labs)


Bioz Verified Symbol Alomone Labs is a verified supplier
Bioz Manufacturer Symbol Alomone Labs manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 95

    Structured Review

    Alomone Labs glun2b n terminus
    Glun2b N Terminus, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 95/100, based on 102 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/glun2b n terminus/product/Alomone Labs
    Average 95 stars, based on 102 article reviews
    glun2b n terminus - by Bioz Stars, 2026-03
    95/100 stars

    Images



    Similar Products

    95
    Alomone Labs glun2b n terminus
    Glun2b N Terminus, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/glun2b n terminus/product/Alomone Labs
    Average 95 stars, based on 1 article reviews
    glun2b n terminus - by Bioz Stars, 2026-03
    95/100 stars
      Buy from Supplier

    90
    Thermo Fisher anti-glun2b (n terminus) – rabbit polyclonal
    Anti Glun2b (N Terminus) – Rabbit Polyclonal, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti-glun2b (n terminus) – rabbit polyclonal/product/Thermo Fisher
    Average 90 stars, based on 1 article reviews
    anti-glun2b (n terminus) – rabbit polyclonal - by Bioz Stars, 2026-03
    90/100 stars
      Buy from Supplier

    90
    Thermo Fisher anti-glun2b (n terminus), 71–8600
    Anti Glun2b (N Terminus), 71–8600, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti-glun2b (n terminus), 71–8600/product/Thermo Fisher
    Average 90 stars, based on 1 article reviews
    anti-glun2b (n terminus), 71–8600 - by Bioz Stars, 2026-03
    90/100 stars
      Buy from Supplier

    90
    MyBiosource Biotechnology glun2b n-terminus mbs800075 antibody
    Glun2b N Terminus Mbs800075 Antibody, supplied by MyBiosource Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/glun2b n-terminus mbs800075 antibody/product/MyBiosource Biotechnology
    Average 90 stars, based on 1 article reviews
    glun2b n-terminus mbs800075 antibody - by Bioz Stars, 2026-03
    90/100 stars
      Buy from Supplier

    90
    Thermo Fisher anti-glun2b (n terminus
    The <t>GluN2B</t> CaMKII Site Is Dispensable for the Developmental Switch In Vitro (A) Schematic of the GluN2B ΔCaMKII amino acid changes. (B and C) Altered GluN2B phosphorylation in GluN2B ΔCaMKII/ΔCaMKII neurons. Cortical neuronal extracts were prepared and analyzed by western blot with the indicated antibodies, normalized to total GluN2B. (B) shows quantitation (mean ± SEM here and throughout), and (C) shows an example. ∗ p < 0.05 versus GluN2B +/+ (n = 4). (D) NMDAR current density at the indicated ages for GluN2B WT/WT and GluN2B ΔCaMKII/ΔCaMKII neurons. ∗ p < 0.05 versus DIV7 or DIV8 of the same genotype; two-way ANOVA plus Sidak’s post hoc test (GluN2B WT/WT : n = 14 [DIV7 or DIV8], n = 18 [DIV14–18]; GluN2B ΔCaMKII/ΔCaMKII : n = 15 [DIV7 or DIV8], n = 17 [DIV14–18]). (E) Extrasynaptic NMDAR currents were measured in GluN2B WT/WT and GluN2B ΔCaMKII/ΔCaMKII neurons (n = 8 per genotype). (F and G) GluN2A and GluN2B expression analyzed by western blot at DIV8 and DIV16 for GluN2B WT/WT and GluN2B ΔCaMKII/ΔCaMKII neurons. (F) shows quantitation and (G) shows an example. ∗ p < 0.05 versus DIV8 of the same genotype; two-way ANOVA plus Sidak’s post hoc test (n = 8). (H and I) Neocortices of GluN2B WT/WT and GluN2B ΔCaMKII/ΔCaMKII mice were subjected to immunoprecipitation with an antibody to the N terminus of GluN2B, followed by analysis of GluN2B and CaMKIIα content. (H) shows an example and (I) shows quantitation. ∗ p < 0.05; n = 8 per genotype. (J) Percentage blockade of NMDAR currents by ifenprodil (3 μM) at the indicated stages for GluN2B WT/WT and GluN2B ΔCaMKII/ΔCaMKII neurons. ∗ p < 0.05 versus DIV7 or DIV8 of the same genotype; two-way ANOVA plus Sidak’s post hoc test (GluN2B WT/WT : n = 14 [DIV7 or DIV8], n = 18 [DIV14–18]; GluN2B ΔCaMKII/ΔCaMKII : n = 15 [DIV7 or DIV8], n = 17 [DIV14–18]). (K and L) Percentage potentiation of NMDAR currents by 100 μM spermine was measured at the indicated stages for GluN2B WT/WT and GluN2B ΔCaMKII/ΔCaMKII neurons. ∗ p < 0.05 versus DIV7 or DIV8 of the same genotype; two-way ANOVA plus Sidak’s post hoc test (GluN2B WT/WT : n = 13 [DIV7 or DIV8], n = 18 [DIV14–18]; GluN2B ΔCaMKII/ΔCaMKII : n = 18 [DIV7 or DIV8], n = 14 [DIV14–18]). (K) shows quantitation and (L) shows example traces; scale bar: 200 pA/2 s. (M and N) Neocortical extracts from P14 and P28 mice were analyzed for GluN2A expression, normalized to β-actin. (M) shows quantitation and (N) shows an example. ∗ p < 0.05 versus P14 of the same genotype; two-way ANOVA plus Sidak’s post hoc test (n = 8). (O and P) Post-synaptic density (PSD) extracts from P14 and P28 mice of the indicated genotype were analyzed for GluN2A and GluN2B expression, normalized to β-actin, and the ratio calculated. (O) shows quantitation and (P) shows an example. ∗ p < 0.05 versus P14 of the same genotype; two-way ANOVA plus Sidak’s post hoc test (n = 8).
    Anti Glun2b (N Terminus, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti-glun2b (n terminus/product/Thermo Fisher
    Average 90 stars, based on 1 article reviews
    anti-glun2b (n terminus - by Bioz Stars, 2026-03
    90/100 stars
      Buy from Supplier

    90
    Thermo Fisher glun2b (n-terminus
    The <t>GluN2B</t> CaMKII Site Is Dispensable for the Developmental Switch In Vitro (A) Schematic of the GluN2B ΔCaMKII amino acid changes. (B and C) Altered GluN2B phosphorylation in GluN2B ΔCaMKII/ΔCaMKII neurons. Cortical neuronal extracts were prepared and analyzed by western blot with the indicated antibodies, normalized to total GluN2B. (B) shows quantitation (mean ± SEM here and throughout), and (C) shows an example. ∗ p < 0.05 versus GluN2B +/+ (n = 4). (D) NMDAR current density at the indicated ages for GluN2B WT/WT and GluN2B ΔCaMKII/ΔCaMKII neurons. ∗ p < 0.05 versus DIV7 or DIV8 of the same genotype; two-way ANOVA plus Sidak’s post hoc test (GluN2B WT/WT : n = 14 [DIV7 or DIV8], n = 18 [DIV14–18]; GluN2B ΔCaMKII/ΔCaMKII : n = 15 [DIV7 or DIV8], n = 17 [DIV14–18]). (E) Extrasynaptic NMDAR currents were measured in GluN2B WT/WT and GluN2B ΔCaMKII/ΔCaMKII neurons (n = 8 per genotype). (F and G) GluN2A and GluN2B expression analyzed by western blot at DIV8 and DIV16 for GluN2B WT/WT and GluN2B ΔCaMKII/ΔCaMKII neurons. (F) shows quantitation and (G) shows an example. ∗ p < 0.05 versus DIV8 of the same genotype; two-way ANOVA plus Sidak’s post hoc test (n = 8). (H and I) Neocortices of GluN2B WT/WT and GluN2B ΔCaMKII/ΔCaMKII mice were subjected to immunoprecipitation with an antibody to the N terminus of GluN2B, followed by analysis of GluN2B and CaMKIIα content. (H) shows an example and (I) shows quantitation. ∗ p < 0.05; n = 8 per genotype. (J) Percentage blockade of NMDAR currents by ifenprodil (3 μM) at the indicated stages for GluN2B WT/WT and GluN2B ΔCaMKII/ΔCaMKII neurons. ∗ p < 0.05 versus DIV7 or DIV8 of the same genotype; two-way ANOVA plus Sidak’s post hoc test (GluN2B WT/WT : n = 14 [DIV7 or DIV8], n = 18 [DIV14–18]; GluN2B ΔCaMKII/ΔCaMKII : n = 15 [DIV7 or DIV8], n = 17 [DIV14–18]). (K and L) Percentage potentiation of NMDAR currents by 100 μM spermine was measured at the indicated stages for GluN2B WT/WT and GluN2B ΔCaMKII/ΔCaMKII neurons. ∗ p < 0.05 versus DIV7 or DIV8 of the same genotype; two-way ANOVA plus Sidak’s post hoc test (GluN2B WT/WT : n = 13 [DIV7 or DIV8], n = 18 [DIV14–18]; GluN2B ΔCaMKII/ΔCaMKII : n = 18 [DIV7 or DIV8], n = 14 [DIV14–18]). (K) shows quantitation and (L) shows example traces; scale bar: 200 pA/2 s. (M and N) Neocortical extracts from P14 and P28 mice were analyzed for GluN2A expression, normalized to β-actin. (M) shows quantitation and (N) shows an example. ∗ p < 0.05 versus P14 of the same genotype; two-way ANOVA plus Sidak’s post hoc test (n = 8). (O and P) Post-synaptic density (PSD) extracts from P14 and P28 mice of the indicated genotype were analyzed for GluN2A and GluN2B expression, normalized to β-actin, and the ratio calculated. (O) shows quantitation and (P) shows an example. ∗ p < 0.05 versus P14 of the same genotype; two-way ANOVA plus Sidak’s post hoc test (n = 8).
    Glun2b (N Terminus, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/glun2b (n-terminus/product/Thermo Fisher
    Average 90 stars, based on 1 article reviews
    glun2b (n-terminus - by Bioz Stars, 2026-03
    90/100 stars
      Buy from Supplier

    90
    Santa Cruz Biotechnology antibody anti- glun2b (n-terminus)
    The <t>GluN2B</t> CaMKII Site Is Dispensable for the Developmental Switch In Vitro (A) Schematic of the GluN2B ΔCaMKII amino acid changes. (B and C) Altered GluN2B phosphorylation in GluN2B ΔCaMKII/ΔCaMKII neurons. Cortical neuronal extracts were prepared and analyzed by western blot with the indicated antibodies, normalized to total GluN2B. (B) shows quantitation (mean ± SEM here and throughout), and (C) shows an example. ∗ p < 0.05 versus GluN2B +/+ (n = 4). (D) NMDAR current density at the indicated ages for GluN2B WT/WT and GluN2B ΔCaMKII/ΔCaMKII neurons. ∗ p < 0.05 versus DIV7 or DIV8 of the same genotype; two-way ANOVA plus Sidak’s post hoc test (GluN2B WT/WT : n = 14 [DIV7 or DIV8], n = 18 [DIV14–18]; GluN2B ΔCaMKII/ΔCaMKII : n = 15 [DIV7 or DIV8], n = 17 [DIV14–18]). (E) Extrasynaptic NMDAR currents were measured in GluN2B WT/WT and GluN2B ΔCaMKII/ΔCaMKII neurons (n = 8 per genotype). (F and G) GluN2A and GluN2B expression analyzed by western blot at DIV8 and DIV16 for GluN2B WT/WT and GluN2B ΔCaMKII/ΔCaMKII neurons. (F) shows quantitation and (G) shows an example. ∗ p < 0.05 versus DIV8 of the same genotype; two-way ANOVA plus Sidak’s post hoc test (n = 8). (H and I) Neocortices of GluN2B WT/WT and GluN2B ΔCaMKII/ΔCaMKII mice were subjected to immunoprecipitation with an antibody to the N terminus of GluN2B, followed by analysis of GluN2B and CaMKIIα content. (H) shows an example and (I) shows quantitation. ∗ p < 0.05; n = 8 per genotype. (J) Percentage blockade of NMDAR currents by ifenprodil (3 μM) at the indicated stages for GluN2B WT/WT and GluN2B ΔCaMKII/ΔCaMKII neurons. ∗ p < 0.05 versus DIV7 or DIV8 of the same genotype; two-way ANOVA plus Sidak’s post hoc test (GluN2B WT/WT : n = 14 [DIV7 or DIV8], n = 18 [DIV14–18]; GluN2B ΔCaMKII/ΔCaMKII : n = 15 [DIV7 or DIV8], n = 17 [DIV14–18]). (K and L) Percentage potentiation of NMDAR currents by 100 μM spermine was measured at the indicated stages for GluN2B WT/WT and GluN2B ΔCaMKII/ΔCaMKII neurons. ∗ p < 0.05 versus DIV7 or DIV8 of the same genotype; two-way ANOVA plus Sidak’s post hoc test (GluN2B WT/WT : n = 13 [DIV7 or DIV8], n = 18 [DIV14–18]; GluN2B ΔCaMKII/ΔCaMKII : n = 18 [DIV7 or DIV8], n = 14 [DIV14–18]). (K) shows quantitation and (L) shows example traces; scale bar: 200 pA/2 s. (M and N) Neocortical extracts from P14 and P28 mice were analyzed for GluN2A expression, normalized to β-actin. (M) shows quantitation and (N) shows an example. ∗ p < 0.05 versus P14 of the same genotype; two-way ANOVA plus Sidak’s post hoc test (n = 8). (O and P) Post-synaptic density (PSD) extracts from P14 and P28 mice of the indicated genotype were analyzed for GluN2A and GluN2B expression, normalized to β-actin, and the ratio calculated. (O) shows quantitation and (P) shows an example. ∗ p < 0.05 versus P14 of the same genotype; two-way ANOVA plus Sidak’s post hoc test (n = 8).
    Antibody Anti Glun2b (N Terminus), supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/antibody anti- glun2b (n-terminus)/product/Santa Cruz Biotechnology
    Average 90 stars, based on 1 article reviews
    antibody anti- glun2b (n-terminus) - by Bioz Stars, 2026-03
    90/100 stars
      Buy from Supplier

    Image Search Results


    The GluN2B CaMKII Site Is Dispensable for the Developmental Switch In Vitro (A) Schematic of the GluN2B ΔCaMKII amino acid changes. (B and C) Altered GluN2B phosphorylation in GluN2B ΔCaMKII/ΔCaMKII neurons. Cortical neuronal extracts were prepared and analyzed by western blot with the indicated antibodies, normalized to total GluN2B. (B) shows quantitation (mean ± SEM here and throughout), and (C) shows an example. ∗ p < 0.05 versus GluN2B +/+ (n = 4). (D) NMDAR current density at the indicated ages for GluN2B WT/WT and GluN2B ΔCaMKII/ΔCaMKII neurons. ∗ p < 0.05 versus DIV7 or DIV8 of the same genotype; two-way ANOVA plus Sidak’s post hoc test (GluN2B WT/WT : n = 14 [DIV7 or DIV8], n = 18 [DIV14–18]; GluN2B ΔCaMKII/ΔCaMKII : n = 15 [DIV7 or DIV8], n = 17 [DIV14–18]). (E) Extrasynaptic NMDAR currents were measured in GluN2B WT/WT and GluN2B ΔCaMKII/ΔCaMKII neurons (n = 8 per genotype). (F and G) GluN2A and GluN2B expression analyzed by western blot at DIV8 and DIV16 for GluN2B WT/WT and GluN2B ΔCaMKII/ΔCaMKII neurons. (F) shows quantitation and (G) shows an example. ∗ p < 0.05 versus DIV8 of the same genotype; two-way ANOVA plus Sidak’s post hoc test (n = 8). (H and I) Neocortices of GluN2B WT/WT and GluN2B ΔCaMKII/ΔCaMKII mice were subjected to immunoprecipitation with an antibody to the N terminus of GluN2B, followed by analysis of GluN2B and CaMKIIα content. (H) shows an example and (I) shows quantitation. ∗ p < 0.05; n = 8 per genotype. (J) Percentage blockade of NMDAR currents by ifenprodil (3 μM) at the indicated stages for GluN2B WT/WT and GluN2B ΔCaMKII/ΔCaMKII neurons. ∗ p < 0.05 versus DIV7 or DIV8 of the same genotype; two-way ANOVA plus Sidak’s post hoc test (GluN2B WT/WT : n = 14 [DIV7 or DIV8], n = 18 [DIV14–18]; GluN2B ΔCaMKII/ΔCaMKII : n = 15 [DIV7 or DIV8], n = 17 [DIV14–18]). (K and L) Percentage potentiation of NMDAR currents by 100 μM spermine was measured at the indicated stages for GluN2B WT/WT and GluN2B ΔCaMKII/ΔCaMKII neurons. ∗ p < 0.05 versus DIV7 or DIV8 of the same genotype; two-way ANOVA plus Sidak’s post hoc test (GluN2B WT/WT : n = 13 [DIV7 or DIV8], n = 18 [DIV14–18]; GluN2B ΔCaMKII/ΔCaMKII : n = 18 [DIV7 or DIV8], n = 14 [DIV14–18]). (K) shows quantitation and (L) shows example traces; scale bar: 200 pA/2 s. (M and N) Neocortical extracts from P14 and P28 mice were analyzed for GluN2A expression, normalized to β-actin. (M) shows quantitation and (N) shows an example. ∗ p < 0.05 versus P14 of the same genotype; two-way ANOVA plus Sidak’s post hoc test (n = 8). (O and P) Post-synaptic density (PSD) extracts from P14 and P28 mice of the indicated genotype were analyzed for GluN2A and GluN2B expression, normalized to β-actin, and the ratio calculated. (O) shows quantitation and (P) shows an example. ∗ p < 0.05 versus P14 of the same genotype; two-way ANOVA plus Sidak’s post hoc test (n = 8).

    Journal: Cell Reports

    Article Title: The Developmental Shift of NMDA Receptor Composition Proceeds Independently of GluN2 Subunit-Specific GluN2 C-Terminal Sequences

    doi: 10.1016/j.celrep.2018.09.089

    Figure Lengend Snippet: The GluN2B CaMKII Site Is Dispensable for the Developmental Switch In Vitro (A) Schematic of the GluN2B ΔCaMKII amino acid changes. (B and C) Altered GluN2B phosphorylation in GluN2B ΔCaMKII/ΔCaMKII neurons. Cortical neuronal extracts were prepared and analyzed by western blot with the indicated antibodies, normalized to total GluN2B. (B) shows quantitation (mean ± SEM here and throughout), and (C) shows an example. ∗ p < 0.05 versus GluN2B +/+ (n = 4). (D) NMDAR current density at the indicated ages for GluN2B WT/WT and GluN2B ΔCaMKII/ΔCaMKII neurons. ∗ p < 0.05 versus DIV7 or DIV8 of the same genotype; two-way ANOVA plus Sidak’s post hoc test (GluN2B WT/WT : n = 14 [DIV7 or DIV8], n = 18 [DIV14–18]; GluN2B ΔCaMKII/ΔCaMKII : n = 15 [DIV7 or DIV8], n = 17 [DIV14–18]). (E) Extrasynaptic NMDAR currents were measured in GluN2B WT/WT and GluN2B ΔCaMKII/ΔCaMKII neurons (n = 8 per genotype). (F and G) GluN2A and GluN2B expression analyzed by western blot at DIV8 and DIV16 for GluN2B WT/WT and GluN2B ΔCaMKII/ΔCaMKII neurons. (F) shows quantitation and (G) shows an example. ∗ p < 0.05 versus DIV8 of the same genotype; two-way ANOVA plus Sidak’s post hoc test (n = 8). (H and I) Neocortices of GluN2B WT/WT and GluN2B ΔCaMKII/ΔCaMKII mice were subjected to immunoprecipitation with an antibody to the N terminus of GluN2B, followed by analysis of GluN2B and CaMKIIα content. (H) shows an example and (I) shows quantitation. ∗ p < 0.05; n = 8 per genotype. (J) Percentage blockade of NMDAR currents by ifenprodil (3 μM) at the indicated stages for GluN2B WT/WT and GluN2B ΔCaMKII/ΔCaMKII neurons. ∗ p < 0.05 versus DIV7 or DIV8 of the same genotype; two-way ANOVA plus Sidak’s post hoc test (GluN2B WT/WT : n = 14 [DIV7 or DIV8], n = 18 [DIV14–18]; GluN2B ΔCaMKII/ΔCaMKII : n = 15 [DIV7 or DIV8], n = 17 [DIV14–18]). (K and L) Percentage potentiation of NMDAR currents by 100 μM spermine was measured at the indicated stages for GluN2B WT/WT and GluN2B ΔCaMKII/ΔCaMKII neurons. ∗ p < 0.05 versus DIV7 or DIV8 of the same genotype; two-way ANOVA plus Sidak’s post hoc test (GluN2B WT/WT : n = 13 [DIV7 or DIV8], n = 18 [DIV14–18]; GluN2B ΔCaMKII/ΔCaMKII : n = 18 [DIV7 or DIV8], n = 14 [DIV14–18]). (K) shows quantitation and (L) shows example traces; scale bar: 200 pA/2 s. (M and N) Neocortical extracts from P14 and P28 mice were analyzed for GluN2A expression, normalized to β-actin. (M) shows quantitation and (N) shows an example. ∗ p < 0.05 versus P14 of the same genotype; two-way ANOVA plus Sidak’s post hoc test (n = 8). (O and P) Post-synaptic density (PSD) extracts from P14 and P28 mice of the indicated genotype were analyzed for GluN2A and GluN2B expression, normalized to β-actin, and the ratio calculated. (O) shows quantitation and (P) shows an example. ∗ p < 0.05 versus P14 of the same genotype; two-way ANOVA plus Sidak’s post hoc test (n = 8).

    Article Snippet: anti-GluN2B (N terminus) , Thermo Fisher Scientific , Cat# 71-8600; RRID: AB_2534001.

    Techniques: In Vitro, Western Blot, Quantitation Assay, Expressing, Immunoprecipitation

    The GluN2B CaMKII Binding Site Is Dispensable for Theta Burst LTP (A–C) Activity-dependent signaling to ERK1/2 does not require GluN2B CTD-specific sequences. DIV9 cortical neurons of the indicated genotypes were treated with TTX (500 nM), KN-62 (10 μM), or MK-801 (10 μM) for 1 hr, after which protein extracts were made and subjected to western blot analysis for phospho-ERK1/2 levels, normalized to total ERK1/2. (A) shows quantitation and (B) and (C) show example blots. ∗ p < 0.05 two-way ANOVA plus Dunnett’s post hoc test. No genotype-dependent effects were observed (p = 0.39) or genotype-drug interactions (p = 0.16; n = 8 GluN2B WT/WT ; n = 4 GluN2B ΔCaMKII/ΔCaMKII ; n = 4 GluN2B 2A(CTR)/2A(CTR) ). (D–F) Cumulative probability plots show amplitude (D) and frequency (E) of miniature EPSCs in GluN2B WT/WT and GluN2B ΔCaMKII/ΔCaMKII slices. Results are from 11 cells from 3 GluN2B WT/WT mice and 13 cells from 3 GluN2B ΔCaMKII/ΔCaMKII mice; p = 0.75 (amplitude); p = 0.94 (frequency); unpaired t test. (F) shows example traces. Scale bar: 10 pA/100 ms. (G) NMDAR:AMPAR EPSC ratios at −80 and +40 mV was measured in GluN2B WT/WT (n = 25; 4 mice) and GluN2B ΔCaMKII/ΔCaMKII (n = 30; 4 mice) neurons (unpaired t test; p = 0.95). (H) Weighted time constant (τw) for the decay of EPSCs recorded in (A) at +40 mV was determined using double exponential fits (unpaired t test; p = 0.63). (I) Example traces. Scale bar: 100 pA/20 ms. (J and K) Theta-burst stimulation elicited pathway-specific LTP of synaptic transmission in hippocampal CA1 area. Normalized magnitude of this potentiation 60–65 min after LTP induction did not differ significantly in GluN2B WT/WT mice (29 slices; n = 9) compared to GluN2B ΔCaMKII/ΔCaMKII (35 slices; n = 11); p = 0.162 (two-way nested ANOVA). (J) shows quantitation of data and (K) shows example traces before and after LTP induction. (K) Traces show example fEPSP traces immediately before and 1 hr after theta-burst stimulation. Scale bar: 0.5 mV/2 ms.

    Journal: Cell Reports

    Article Title: The Developmental Shift of NMDA Receptor Composition Proceeds Independently of GluN2 Subunit-Specific GluN2 C-Terminal Sequences

    doi: 10.1016/j.celrep.2018.09.089

    Figure Lengend Snippet: The GluN2B CaMKII Binding Site Is Dispensable for Theta Burst LTP (A–C) Activity-dependent signaling to ERK1/2 does not require GluN2B CTD-specific sequences. DIV9 cortical neurons of the indicated genotypes were treated with TTX (500 nM), KN-62 (10 μM), or MK-801 (10 μM) for 1 hr, after which protein extracts were made and subjected to western blot analysis for phospho-ERK1/2 levels, normalized to total ERK1/2. (A) shows quantitation and (B) and (C) show example blots. ∗ p < 0.05 two-way ANOVA plus Dunnett’s post hoc test. No genotype-dependent effects were observed (p = 0.39) or genotype-drug interactions (p = 0.16; n = 8 GluN2B WT/WT ; n = 4 GluN2B ΔCaMKII/ΔCaMKII ; n = 4 GluN2B 2A(CTR)/2A(CTR) ). (D–F) Cumulative probability plots show amplitude (D) and frequency (E) of miniature EPSCs in GluN2B WT/WT and GluN2B ΔCaMKII/ΔCaMKII slices. Results are from 11 cells from 3 GluN2B WT/WT mice and 13 cells from 3 GluN2B ΔCaMKII/ΔCaMKII mice; p = 0.75 (amplitude); p = 0.94 (frequency); unpaired t test. (F) shows example traces. Scale bar: 10 pA/100 ms. (G) NMDAR:AMPAR EPSC ratios at −80 and +40 mV was measured in GluN2B WT/WT (n = 25; 4 mice) and GluN2B ΔCaMKII/ΔCaMKII (n = 30; 4 mice) neurons (unpaired t test; p = 0.95). (H) Weighted time constant (τw) for the decay of EPSCs recorded in (A) at +40 mV was determined using double exponential fits (unpaired t test; p = 0.63). (I) Example traces. Scale bar: 100 pA/20 ms. (J and K) Theta-burst stimulation elicited pathway-specific LTP of synaptic transmission in hippocampal CA1 area. Normalized magnitude of this potentiation 60–65 min after LTP induction did not differ significantly in GluN2B WT/WT mice (29 slices; n = 9) compared to GluN2B ΔCaMKII/ΔCaMKII (35 slices; n = 11); p = 0.162 (two-way nested ANOVA). (J) shows quantitation of data and (K) shows example traces before and after LTP induction. (K) Traces show example fEPSP traces immediately before and 1 hr after theta-burst stimulation. Scale bar: 0.5 mV/2 ms.

    Article Snippet: anti-GluN2B (N terminus) , Thermo Fisher Scientific , Cat# 71-8600; RRID: AB_2534001.

    Techniques: Binding Assay, Activity Assay, Western Blot, Quantitation Assay, Transmission Assay

    Distinct GluN2 CTDs Are Not Required for the 2B-to-2A Switch (A) Schematic illustrating the C-terminal domain exchange in the GluN2A 2B(CTR)/2B(CTR) mouse. (B) NMDAR current density in GluN2A WT/WT (n = 30) and GluN2A 2B(CTR)/2B(CTR) (n = 24) neurons, recorded DIV14–18. (C and D) Percentage potentiation of NMDAR currents by 100 μM spermine was measured in GluN2A WT/WT and GluN2A 2B(CTR)/2B(CTR) neurons. ∗ p < 0.05 versus DIV7 or DIV8 of the same genotype; two-way ANOVA plus Sidak’s post hoc test (GluN2A WT/WT : n = 19 [DIV7 or DIV8], n = 18 [DIV14–18]; GluN2A 2B(CTR)/2B(CTR) : n = 16 [DIV7 or DIV8], n = 17 [DIV14–18]). (C) shows quantitation of data and (D) shows example traces; scale bar: 200 pA/2 s. (E and F) Neocortical extracts from P14 and P28 mice of the indicated genotype were analyzed for GluN2A expression, normalized to β-actin. ∗ p < 0.05 versus P14 of the same genotype; two-way ANOVA plus Sidak’s post hoc test (n = 8). (E) shows quantitation and (F) shows example blots. (G and H) PSD extracts from P14 and P28 mice of the indicated genotype were analyzed for GluN2A and GluN2B expression, normalized to β-actin, and the ratio calculated and scaled such that the ratio at P14 for WT = 1. ∗ p < 0.05 versus P14 of the same genotype; two-way ANOVA plus Sidak’s post hoc test (n = 8). (G) shows quantitation and (H) shows an example blot.

    Journal: Cell Reports

    Article Title: The Developmental Shift of NMDA Receptor Composition Proceeds Independently of GluN2 Subunit-Specific GluN2 C-Terminal Sequences

    doi: 10.1016/j.celrep.2018.09.089

    Figure Lengend Snippet: Distinct GluN2 CTDs Are Not Required for the 2B-to-2A Switch (A) Schematic illustrating the C-terminal domain exchange in the GluN2A 2B(CTR)/2B(CTR) mouse. (B) NMDAR current density in GluN2A WT/WT (n = 30) and GluN2A 2B(CTR)/2B(CTR) (n = 24) neurons, recorded DIV14–18. (C and D) Percentage potentiation of NMDAR currents by 100 μM spermine was measured in GluN2A WT/WT and GluN2A 2B(CTR)/2B(CTR) neurons. ∗ p < 0.05 versus DIV7 or DIV8 of the same genotype; two-way ANOVA plus Sidak’s post hoc test (GluN2A WT/WT : n = 19 [DIV7 or DIV8], n = 18 [DIV14–18]; GluN2A 2B(CTR)/2B(CTR) : n = 16 [DIV7 or DIV8], n = 17 [DIV14–18]). (C) shows quantitation of data and (D) shows example traces; scale bar: 200 pA/2 s. (E and F) Neocortical extracts from P14 and P28 mice of the indicated genotype were analyzed for GluN2A expression, normalized to β-actin. ∗ p < 0.05 versus P14 of the same genotype; two-way ANOVA plus Sidak’s post hoc test (n = 8). (E) shows quantitation and (F) shows example blots. (G and H) PSD extracts from P14 and P28 mice of the indicated genotype were analyzed for GluN2A and GluN2B expression, normalized to β-actin, and the ratio calculated and scaled such that the ratio at P14 for WT = 1. ∗ p < 0.05 versus P14 of the same genotype; two-way ANOVA plus Sidak’s post hoc test (n = 8). (G) shows quantitation and (H) shows an example blot.

    Article Snippet: anti-GluN2B (N terminus) , Thermo Fisher Scientific , Cat# 71-8600; RRID: AB_2534001.

    Techniques: Quantitation Assay, Expressing

    GluN2A Expression Is Sufficient to Displace GluN2B from NMDARs (A–D) Total GluN2B expression was measured in extracts from the neocortex at the indicated stages for the indicated genotypes (n = 8 per genotype). (A) and (B) show quantitation and example blots, respectively, for GluN2A WT/WT versus GluN2A 2B(CTR)/2B(CTR) . (C) and (D) show quantitation and example blots, respectively, for GluN2A WT/WT vs. GluN2B ΔCaMKII/ΔCaMKII . (E–G) Ectopic GluN2A expression is sufficient to displace GluN2B from NMDARs. Young mouse (E and F) and rat (G) neurons at DIV7 were transfected with a control (β-globin) or GluN2A-encoding vector and spermine (100 μM) potentiation of NMDAR currents measured 72 hr later. ∗ p < 0.05 (F: n = 10 of both condition; G: n = 8 control; n = 10 GluN2A). (H) Percentage potentiation of NMDAR currents by spermine (200 μM) in DIV15 or DIV16 rat cortical neurons was measured at the indicated stages for GluN2A +/+ , GluN2A +/− , and GluN2A −/− genotypes. Person r correlation coefficient: −0.9954; p = 0.031 (one-tailed test); n = 12 cells per genotype. (I) Western blot illustrating GluN2A expression in GluN2A +/+ , GluN2A +/– , and GluN2A –/– neurons. (I) A western blot confirming the absence of GluN2A expression in GluN2A −/− and an intermediate expression level in GluN2A +/− neurons.

    Journal: Cell Reports

    Article Title: The Developmental Shift of NMDA Receptor Composition Proceeds Independently of GluN2 Subunit-Specific GluN2 C-Terminal Sequences

    doi: 10.1016/j.celrep.2018.09.089

    Figure Lengend Snippet: GluN2A Expression Is Sufficient to Displace GluN2B from NMDARs (A–D) Total GluN2B expression was measured in extracts from the neocortex at the indicated stages for the indicated genotypes (n = 8 per genotype). (A) and (B) show quantitation and example blots, respectively, for GluN2A WT/WT versus GluN2A 2B(CTR)/2B(CTR) . (C) and (D) show quantitation and example blots, respectively, for GluN2A WT/WT vs. GluN2B ΔCaMKII/ΔCaMKII . (E–G) Ectopic GluN2A expression is sufficient to displace GluN2B from NMDARs. Young mouse (E and F) and rat (G) neurons at DIV7 were transfected with a control (β-globin) or GluN2A-encoding vector and spermine (100 μM) potentiation of NMDAR currents measured 72 hr later. ∗ p < 0.05 (F: n = 10 of both condition; G: n = 8 control; n = 10 GluN2A). (H) Percentage potentiation of NMDAR currents by spermine (200 μM) in DIV15 or DIV16 rat cortical neurons was measured at the indicated stages for GluN2A +/+ , GluN2A +/− , and GluN2A −/− genotypes. Person r correlation coefficient: −0.9954; p = 0.031 (one-tailed test); n = 12 cells per genotype. (I) Western blot illustrating GluN2A expression in GluN2A +/+ , GluN2A +/– , and GluN2A –/– neurons. (I) A western blot confirming the absence of GluN2A expression in GluN2A −/− and an intermediate expression level in GluN2A +/− neurons.

    Article Snippet: anti-GluN2B (N terminus) , Thermo Fisher Scientific , Cat# 71-8600; RRID: AB_2534001.

    Techniques: Expressing, Quantitation Assay, Transfection, Plasmid Preparation, One-tailed Test, Western Blot

    Journal: Cell Reports

    Article Title: The Developmental Shift of NMDA Receptor Composition Proceeds Independently of GluN2 Subunit-Specific GluN2 C-Terminal Sequences

    doi: 10.1016/j.celrep.2018.09.089

    Figure Lengend Snippet:

    Article Snippet: anti-GluN2B (N terminus) , Thermo Fisher Scientific , Cat# 71-8600; RRID: AB_2534001.

    Techniques: Recombinant